PT-141 vs Melanotan 2 research peptide vials — melanocortin receptor agonist comparison for Canadian laboratory research use.

PT-141 vs Melanotan 2: Melanocortin Peptide Comparison Guide

PT-141 and Melanotan 2 are the two most-studied melanocortin receptor agonist research peptides in modern pharmacology, and they're frequently compared by researchers and informed buyers evaluating melanocortin research tools. While both compounds activate melanocortin receptors, they operate through meaningfully different receptor selectivity profiles — and understanding those differences is essential to selecting the right tool for specific research designs.

This guide provides a comprehensive comparison of PT-141 vs Melanotan 2 across receptor pharmacology, molecular structure, research applications, and sourcing considerations for Canadian laboratories. Whether you're choosing between PT-141 research peptide and Melanotan 2 research peptide for specific research applications, this guide covers what you need to know.

The short version: PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan 2 through structural modification, engineered for improved selectivity toward MC3R and MC4R receptors. Melanotan 2 is a broader-spectrum melanocortin agonist active across MC1R, MC3R, MC4R, and MC5R receptors. The two compounds are pharmacologically related but functionally distinct — PT-141 provides more selective research access to central melanocortin biology, while Melanotan 2 provides broader multi-receptor research applications. The long version explains the pharmacology, evidence base, and research context in detail.

Table of Contents

PT-141 vs Melanotan 2: Quick Comparison Table

Feature PT-141 (Bremelanotide) Melanotan 2
Full name Bremelanotide Melanotan II (MT-2)
Type Synthetic cyclic heptapeptide Synthetic cyclic heptapeptide
Origin Derived from Melanotan 2 through structural modification Synthetic α-MSH analog
Primary receptor selectivity MC3R and MC4R preferential Non-selective across MC1R, MC3R, MC4R, MC5R
Structural relationship Contains free carboxylic acid (open-chain modification) Fully cyclic structure
First identified/developed Late 1990s (Palatin Technologies) 1980s (University of Arizona)
Regulatory status FDA-approved as Vyleesi (2019) for specific indication Investigational only — not approved
Strongest research focus MC3R/MC4R pharmacology, CNS signaling Multi-receptor melanocortin research, MC1R pigmentation
Best research fit Selective central melanocortin research Broad melanocortin receptor family research

What is PT-141?

PT-141 is a synthetic cyclic heptapeptide known internationally by the nonproprietary name bremelanotide. The compound was developed by Palatin Technologies through structural modification of Melanotan 2, engineered specifically to shift the receptor selectivity profile toward central melanocortin receptors.

PT-141 Discovery and Development

PT-141's development history connects directly to Melanotan 2 research. In the late 1990s, researchers at Palatin Technologies investigated modifications to Melanotan 2 that could shift its receptor selectivity profile. The key insight was that opening the cyclic structure at specific positions and introducing structural modifications could preserve activity at MC3R and MC4R while reducing activity at MC1R and MC5R.

The resulting compound — bremelanotide (PT-141) — retained potent central melanocortin activity while showing reduced peripheral melanocortin effects compared to its Melanotan 2 parent. This selectivity shift made PT-141 particularly interesting for research focused on central nervous system melanocortin signaling.

PT-141 subsequently progressed through clinical development and received FDA approval in 2019 under the brand name Vyleesi for a specific medical indication in adult women, becoming one of the few melanocortin agonists to achieve regulatory approval.

PT-141 Molecular Structure

PT-141 is a synthetic cyclic heptapeptide with a specific structural modification distinguishing it from Melanotan 2:

  • Seven-amino-acid core sequence preserving key melanocortin receptor binding elements
  • Cyclic backbone maintaining conformational rigidity important for receptor binding
  • Free carboxylic acid modification — the specific structural change that shifts receptor selectivity
  • Standard L-amino acids with selected D-amino acid substitutions for enhanced stability

These structural features together produce a compound with pharmacological properties distinct from Melanotan 2 despite the close structural relationship.

PT-141 Mechanism

PT-141 operates as an agonist at MC3R and MC4R receptors, with the following mechanistic characteristics:

  • Central nervous system focus — MC3R and MC4R are highly expressed in the hypothalamus and brainstem
  • Reduced peripheral effects compared to Melanotan 2 due to lower MC1R and MC5R activity
  • cAMP signaling activation as the primary downstream signaling pathway
  • Selective receptor engagement that enables cleaner mechanism research than broader melanocortin agonists

For research applications specifically focused on central melanocortin biology, PT-141's receptor selectivity profile provides a cleaner research tool than compounds with broader receptor activity.

What is Melanotan 2?

Melanotan 2 is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH), one of the earliest and most-studied synthetic melanocortin agonists in research pharmacology.

Melanotan 2 Discovery and Development

Melanotan 2 was originally developed in the 1980s at the University of Arizona by Mac Hadley, Victor Hruby, and colleagues. The research group was investigating synthetic α-MSH analogs with improved pharmacological properties compared to native α-MSH — which suffers from rapid enzymatic degradation and limited biological activity due to structural instability.

The research produced two compounds that became widely used research tools: Melanotan I (afamelanotide, later approved as Scenesse for a specific indication) and Melanotan II (MT-2, or Melanotan 2). While Melanotan I retained more selective MC1R activity, Melanotan 2 emerged as a broader-spectrum melanocortin agonist with activity across the full receptor family.

Melanotan 2 has been extensively studied in research contexts for over three decades but has not received regulatory approval for any specific indication. The compound remains available as a research peptide for laboratory investigation of melanocortin biology.

Melanotan 2 Molecular Structure

Melanotan 2 is a synthetic cyclic heptapeptide with specific structural characteristics:

  • Seven-amino-acid core sequence derived from α-MSH
  • Fully cyclic backbone providing conformational rigidity
  • Selected D-amino acid substitutions that resist enzymatic degradation
  • Modified N-terminus compared to native α-MSH for enhanced stability and activity

These modifications produce a compound with substantially greater stability and potency than native α-MSH while maintaining broad melanocortin receptor engagement.

Melanotan 2 Mechanism

Melanotan 2 operates as a non-selective agonist across the melanocortin receptor family:

  • MC1R activation — melanogenesis and pigmentation research applications
  • MC3R activation — energy homeostasis and inflammatory response research
  • MC4R activation — appetite regulation and central signaling research
  • MC5R activation — exocrine function and peripheral effects research

This broad receptor activity makes Melanotan 2 particularly useful for research designs investigating melanocortin biology broadly, rather than specific receptor subtypes.

Understanding Melanocortin Receptor Pharmacology

Before comparing PT-141 and Melanotan 2 directly, understanding the melanocortin receptor family helps clarify why receptor selectivity matters so much for these compounds.

The Five Melanocortin Receptors

Mammalian genomes encode five distinct melanocortin receptors, each with different tissue distribution and biological functions:

MC1R (Melanocortin Receptor 1). Primarily expressed on melanocytes, MC1R activation drives melanogenesis — the production of melanin pigmentation. MC1R activity is central to skin pigmentation research and related biological processes.

MC2R (Melanocortin Receptor 2). Also known as the ACTH receptor, MC2R is primarily expressed in adrenal cortex tissue where it drives cortisol production. MC2R has different ligand specificity than other melanocortin receptors and isn't a target for typical melanocortin research peptides.

MC3R (Melanocortin Receptor 3). Expressed in the central nervous system, particularly in the hypothalamus. MC3R contributes to energy homeostasis, inflammatory responses, and various central signaling functions.

MC4R (Melanocortin Receptor 4). Expressed primarily in the central nervous system, particularly in hypothalamic and brainstem regions involved in appetite regulation and central signaling. MC4R is implicated in appetite research and central melanocortin biology.

MC5R (Melanocortin Receptor 5). Expressed in various peripheral tissues including exocrine glands. MC5R functions remain less well-characterized than the other receptors.

Why Receptor Selectivity Matters for Research

Because the five melanocortin receptors have such different tissue distribution and biological functions, receptor selectivity profoundly affects what a compound can research:

  • Broadly-active compounds like Melanotan 2 engage all melanocortin receptors, useful for research investigating melanocortin biology as an integrated system but confounding for research investigating specific receptor subtypes
  • Selective compounds like PT-141 preferentially engage specific receptors, useful for research investigating specific mechanism biology without confounding effects from other receptors

Neither approach is inherently superior — the choice depends on the specific research question. Research investigating central melanocortin signaling benefits from MC3R/MC4R-selective compounds like PT-141. Research investigating melanocortin biology across multiple tissue systems benefits from broadly-active compounds like Melanotan 2.

Mechanism Comparison: Receptor Selectivity Differences

The central mechanistic difference between PT-141 and Melanotan 2 lies in their receptor selectivity profiles.

PT-141 Receptor Selectivity

PT-141 shows meaningfully greater selectivity for MC3R and MC4R compared to MC1R and MC5R:

  • MC4R activity: Strong agonist activity
  • MC3R activity: Strong agonist activity
  • MC1R activity: Reduced compared to Melanotan 2
  • MC5R activity: Reduced compared to Melanotan 2

This selectivity profile means research designs using PT-141 can more confidently attribute observed effects to MC3R and MC4R mechanisms rather than other melanocortin receptor activity.

Melanotan 2 Receptor Activity

Melanotan 2 shows broad activity across the melanocortin receptor family:

  • MC1R activity: Strong agonist activity
  • MC3R activity: Strong agonist activity
  • MC4R activity: Strong agonist activity
  • MC5R activity: Strong agonist activity

This broad activity makes Melanotan 2 useful as a comprehensive melanocortin research tool but means observed effects cannot be attributed to any single receptor without additional mechanism deconvolution.

Downstream Signaling Comparison

Both PT-141 and Melanotan 2 activate melanocortin receptors through the same fundamental signaling mechanism:

  • G-protein coupled receptor activation — both compounds function as agonists at melanocortin GPCRs
  • cAMP signaling as the primary downstream pathway
  • Protein kinase A activation following cAMP elevation
  • Downstream transcription factor modulation affecting cellular responses

The mechanistic differences between the two compounds derive from which receptors they activate, not how they activate them once bound.

Time Course Differences

PT-141 and Melanotan 2 also differ in pharmacokinetic characteristics that affect research design:

  • PT-141: Shorter half-life, faster onset of effects, briefer duration
  • Melanotan 2: Longer half-life, more sustained effects, longer research protocol implications

Research designs investigating acute mechanism activation may prefer PT-141's shorter time course. Research designs investigating sustained melanocortin activity may prefer Melanotan 2's longer duration.

Research Applications: When to Use Which Compound

Given the mechanism differences, when does a research design choose PT-141 versus Melanotan 2?

When to Choose PT-141

PT-141 is the better choice for research designs investigating:

Central melanocortin signaling specifically. Research designs investigating MC3R or MC4R biology benefit from PT-141's receptor selectivity. Broader melanocortin agonists confound mechanism attribution in central signaling research.

MC4R-mediated pathways. Research designs investigating central nervous system MC4R biology use PT-141 as a preferred research tool given its receptor selectivity profile.

Appetite and energy homeostasis research. The central nervous system MC3R and MC4R populations that PT-141 preferentially engages are directly relevant to appetite regulation research.

Reduced peripheral effect research. When research designs need to investigate central melanocortin biology without concurrent peripheral melanocortin effects, PT-141's reduced MC1R and MC5R activity provides a cleaner research profile.

Comparative selectivity studies. Research designs comparing selective vs non-selective melanocortin agonism use PT-141 as the selective reference compound against Melanotan 2 as the non-selective reference.

When to Choose Melanotan 2

Melanotan 2 is the better choice for research designs investigating:

Broad melanocortin biology. Research designs investigating melanocortin receptor family biology as an integrated system benefit from Melanotan 2's non-selective activity across all four target receptors.

MC1R pigmentation research. Research designs investigating melanogenesis, melanocyte biology, or pigmentation pathways specifically use Melanotan 2 given its strong MC1R activity that PT-141 lacks.

Multi-receptor mechanism studies. Research investigating how multiple melanocortin receptors interact requires a broadly-active tool. Melanotan 2 enables this research where selective compounds cannot.

Peripheral melanocortin research. Research designs investigating MC5R biology and peripheral melanocortin effects use Melanotan 2 given the compound's broad receptor activity.

Historical reference research. Melanotan 2 has an extensive research literature base spanning multiple decades. Research designs replicating or extending previous work often use Melanotan 2 for continuity with the established evidence base.

When the Choice is Ambiguous

Some research designs could reasonably use either compound:

  • General melanocortin pharmacology research (both work)
  • Cross-comparison studies (both are commonly used)
  • Basic melanocortin biology investigation

In these ambiguous cases, the decision often comes down to:

  • Which specific mechanism the research design wants to investigate
  • Whether receptor selectivity or breadth better serves the research question
  • Time course preferences for the research protocol
  • Availability of comparative reference data from previous studies

Evidence Base Comparison: Published Literature

The published research literature on PT-141 vs Melanotan 2 differs in important ways.

PT-141 Evidence Base

PT-141 has accumulated substantial published evidence, with particular concentration in:

  • Central melanocortin receptor pharmacology
  • MC3R and MC4R selectivity research
  • Clinical development evidence (Phase 2 and Phase 3 trials for the approved indication)
  • CNS signaling mechanism studies
  • Comparative selectivity research against other melanocortin agonists

The compound's progression through clinical development and FDA approval provides evidence quality and depth that many research peptides lack. Peer-reviewed publications on PT-141 are searchable through PubMed bremelanotide research.

Melanotan 2 Evidence Base

Melanotan 2 has an extensive research literature base spanning multiple decades:

  • Broad melanocortin receptor pharmacology
  • MC1R pigmentation research (particularly extensive)
  • Comparative pharmacology across the melanocortin receptor family
  • Multi-tissue biological effect research
  • Historical reference status for melanocortin research

The compound's decades-long research history makes it a foundational reference in the melanocortin research literature. Publications on Melanotan 2 are searchable through PubMed Melanotan II research.

Evidence Depth Trade-Off

The trade-off between the two compounds' evidence bases reflects their different research applications:

  • PT-141 offers depth in specific research domains — particularly central melanocortin signaling and clinical development evidence
  • Melanotan 2 offers breadth across melanocortin research more broadly, with extensive historical literature

Research designs benefiting from clinical-stage evidence quality favor PT-141. Research designs benefiting from breadth of published literature and historical context favor Melanotan 2.

Pharmacokinetic Differences

Beyond receptor selectivity, PT-141 and Melanotan 2 differ in pharmacokinetic characteristics that affect research design.

Half-Life and Duration

PT-141 has a relatively short half-life compared to Melanotan 2:

  • PT-141: Approximately 1-3 hour half-life in research contexts
  • Melanotan 2: Longer half-life supporting sustained melanocortin activity

This difference affects research design significantly. Research investigating acute mechanism activation may prefer PT-141's briefer time course. Research investigating sustained melanocortin signaling may prefer Melanotan 2's longer duration.

Stability and Storage

Both compounds have similar stability characteristics as lyophilized peptides:

  • Stable at 2-8°C (refrigerator) for 12+ months protected from light
  • Stable at -20°C (freezer) for 24+ months protected from light
  • Reduced stability once reconstituted

Neither compound requires unusual storage conditions compared to standard research peptides. For complete storage guidance, see How to Store Research Peptides: A Complete Stability and Handling Guide.

Delivery and Administration in Research

Both compounds are typically administered via subcutaneous injection in research contexts, following similar research protocols. The choice between the two compounds is driven by receptor selectivity and time course requirements rather than administration considerations.

Sourcing PT-141 and Melanotan 2 for Canadian Research

When sourcing PT-141 and Melanotan 2 for Canadian research, four sourcing criteria distinguish quality suppliers from problematic ones.

HPLC purity verification. Research-grade PT-141 and Melanotan 2 should be ≥99% pure as measured by high-performance liquid chromatography. Both compounds are well-established synthetic peptides and ≥99% purity is achievable at scale, but not all suppliers actually verify this on every batch.

Mass spectrometry identity confirmation. HPLC measures purity but not identity. Mass spectrometry verifies molecular weight matches the intended peptide. This is particularly important for structurally similar compounds like PT-141 and Melanotan 2, where synthesis errors could produce related but functionally different products.

Batch-specific certificates of analysis. Generic certificates that don't reference specific batch numbers provide no quality assurance. Quality suppliers provide COAs traceable to specific manufacturing lots.

Domestic Canadian supply chain. Lyophilized peptides are sensitive to thermal cycling during shipping. Domestic Canadian shipping eliminates cold-chain variables that compromise international shipments. For more on supplier evaluation criteria, see Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers.

Emerald Peptides supplies PT-141 research peptide and Melanotan 2 research peptide at ≥99% HPLC purity with mass-spec-verified identity, batch-specific COAs, and fast domestic Canadian shipping. Both compounds are sold strictly for research use only.

Frequently Asked Questions

What is the difference between PT-141 and Melanotan 2?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan 2 through structural modification. The two compounds differ primarily in receptor selectivity: PT-141 shows preferential activity at MC3R and MC4R receptors with reduced activity at MC1R and MC5R, while Melanotan 2 shows broad activity across all four target melanocortin receptors. PT-141 also has FDA approval for a specific indication under the brand name Vyleesi, while Melanotan 2 remains investigational only. For research purposes, the two compounds serve different applications based on their receptor selectivity profiles.

Is PT-141 the same as Melanotan 2?

No. PT-141 is structurally derived from Melanotan 2 but is a distinct compound with different pharmacological properties. The key difference is receptor selectivity — PT-141 preferentially activates MC3R and MC4R, while Melanotan 2 activates all four target melanocortin receptors (MC1R, MC3R, MC4R, and MC5R). PT-141 also has a shorter half-life and different pharmacokinetic profile than Melanotan 2. The two compounds are pharmacologically related but functionally distinct research tools.

Which compound has more selective receptor activity?

PT-141 has more selective receptor activity than Melanotan 2. PT-141 shows preferential activity at MC3R and MC4R with reduced activity at MC1R and MC5R. Melanotan 2 shows broad activity across all four target melanocortin receptors. For research designs requiring receptor-selective compounds, PT-141 is the more appropriate choice. For research designs benefiting from broad melanocortin receptor family activity, Melanotan 2 provides broader access to melanocortin biology.

Are PT-141 and Melanotan 2 approved for human use?

PT-141 (bremelanotide) received FDA approval in 2019 under the brand name Vyleesi for a specific medical indication. Melanotan 2 has not received regulatory approval for any indication and remains investigational only. However, research peptides sold for laboratory research use only are not the same as approved pharmaceutical products. Research peptide suppliers do not sell either PT-141 or Melanotan 2 for human therapeutic purposes. For approved therapeutic options for any specific condition, consult licensed medical professionals.

How do PT-141 and Melanotan 2 differ pharmacokinetically?

PT-141 has a relatively short half-life (approximately 1-3 hours in research contexts), while Melanotan 2 has a longer half-life supporting sustained melanocortin activity. This difference affects research design significantly — research investigating acute mechanism activation may prefer PT-141's briefer time course, while research investigating sustained melanocortin signaling may prefer Melanotan 2's longer duration. Both compounds have similar stability characteristics as lyophilized peptides under standard storage conditions.

What research applications are best served by PT-141?

PT-141 is best suited for research designs investigating central melanocortin signaling specifically, MC4R-mediated pathways, appetite and energy homeostasis research, reduced peripheral effect research, and comparative selectivity studies. The compound's preferential MC3R and MC4R activity makes it particularly useful for research where receptor selectivity matters for mechanism attribution. For MC1R pigmentation research or broad multi-receptor investigation, Melanotan 2 is typically the more appropriate choice.

What research applications are best served by Melanotan 2?

Melanotan 2 is best suited for research designs investigating broad melanocortin biology across multiple receptors, MC1R pigmentation research specifically, multi-receptor mechanism studies, peripheral melanocortin research through MC5R, and research replicating or extending the extensive historical Melanotan 2 literature. The compound's broad receptor activity makes it particularly useful for research investigating melanocortin biology as an integrated system rather than specific receptor subtypes.

Can PT-141 and Melanotan 2 be used together in research?

Research designs occasionally use both compounds together for specific comparative studies — particularly research investigating the effects of selective vs non-selective melanocortin agonism. In such designs, PT-141 serves as the selective reference compound and Melanotan 2 serves as the non-selective reference. However, unlike the BPC-157 + TB-500 combination which combines complementary non-overlapping mechanisms, PT-141 and Melanotan 2 target overlapping receptors — so combination use requires careful research design to avoid confounding effects. Most research designs use one compound or the other rather than combining them.

Where can researchers buy PT-141 and Melanotan 2 in Canada?

Canadian research labs sourcing PT-141 and Melanotan 2 should look for suppliers meeting key criteria: ≥99% HPLC purity confirmation on every batch, mass spectrometry verification of identity, batch-specific certificates of analysis, and domestic Canadian shipping. Emerald Peptides supplies PT-141 research peptide and Melanotan 2 research peptide for research use only, with the same quality standards across both compounds. For broader supplier evaluation criteria, see our Emerald Peptides vs. Other Brands post.

Where can I read more about melanocortin research?

Peer-reviewed research on melanocortin receptors is searchable through PubMed, the U.S. National Library of Medicine's authoritative database. Specific searches include PubMed bremelanotide research for PT-141 studies and PubMed Melanotan II research for Melanotan 2 studies. For comprehensive coverage of receptor biology fundamentals, published research through the National Center for Biotechnology Information provides foundational context.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.

Back to blog